TG-101348, 98%, a selective inhibitor of JAK2 with an IC50 of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.

Name: TG-101348, 98%, a selective inhibitor of JAK2 with an IC50 of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively. | 936091-26-8
Brand: J&K Chemical
SKU: JK9000042_5_MG
Price: 127.2 USD
Availability: OutOfStock

Cat. No JK9000042_5_MG

Vendor: J&K Chemical

Product Information

Product Name

TG-101348, 98%, a selective inhibitor of JAK2 with an IC50 of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.

Brand Name

J&K

Product Number

9000042

CAS

936091-26-8

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

16722836

IUPAC Name

N-tert-butyl-3-5-methyl-2-4-(2-pyrrolidin-1-ylethoxy)anilinopyrimidin-4-ylaminobenzenesulfonamide

InChI Key

JOOXLOJCABQBSG-UHFFFAOYSA-N

SMILES

CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4

Safety Information

Storage Condition

Freezer -20℃

References

Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia

Publication Name: International Journal of Hematology

Publication Date: 2025-07-21

DOI: 10.1007/s12185-025-04037-6

Deciphering TLR and JAK/STAT pathways: genetic variants and targeted therapies in COVID-19

Publication Name: Molecular Biology Reports

Publication Date: 2025-07-18

DOI: 10.1007/s11033-025-10843-2

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma

Publication Name: International Journal of Clinical Oncology

Publication Date: 2025-07-12

DOI: 10.1007/s10147-025-02830-1

A comprehensive overview of patient journey and management decision pathway for myelofibrosis in India: INLAND survey

Publication Name: BMC Cancer

Publication Date: 2025-07-10

DOI: 10.1186/s12885-025-14476-3

Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial

Publication Name: Cancer Chemotherapy and Pharmacology

Publication Date: 2025-07-02

DOI: 10.1007/s00280-025-04785-6

TG-101348, 98%, a selective inhibitor of JAK2 with an IC50 of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.

Product Information

General Information

Safety Information

References

Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia

Deciphering TLR and JAK/STAT pathways: genetic variants and targeted therapies in COVID-19

A comprehensive overview of patient journey and management decision pathway for myelofibrosis in India: INLAND survey

Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial